Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison

Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison

Bibliographic Details
Main Authors:	Philip Mease, Ernest Choy, Peter Nash, Chrysostomos Kalyvas, Matthias Hunger, Luminita Pricop, Kunal K. Gandhi, Steffen M. Jugl, Howard Thom
Format:	Article
Language:	English
Published:	AVES 2019-07-01
Series:	European Journal of Rheumatology
Online Access:	https://www.eurjrheumatol.org/eng/makale/3224/219/Full-Text

Similar Items

Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2‐year results from a multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled phase III study
by: Coates, L, et al.
Published: (2018)

Etanercept (Enbrel) in the treatment of psoriatic arthritis
by: T V Korotaeva
Published: (2009-12-01)

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
by: Coates, L, et al.
Published: (2019)

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients
by: Orbai, A-M, et al.
Published: (2019)

RESULTS OF EVALUATING THE EFFICACY OF SECUKINUMAB VERSUS ADALIMUMAB IN TREATING PSORIATIC ARTHRITIS BY USING THE MATCHING-ADJUSTED INDIRECT COMPARISON METHOD
by: T. V. Korotaeva
Published: (2016-12-01)

Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis
by: Philip Mease, et al.
Published: (2022-12-01)

Secukinumab treatment in psoriatic patients: Italian experiences
by: Luca Idolazzi
Published: (2018-11-01)

Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
by: Pournara, E, et al.
Published: (2021)

Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study
by: Coates, L, et al.
Published: (2020)

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
by: Coates, L, et al.
Published: (2018)

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
by: Mease, P, et al.
Published: (2018)

Secukinumab in multi-failure psoriatic patients: the last hope?
by: M. Magnano, et al.
Published: (2018-08-01)

Treatment of psoriatic arthritis with secukinumab: a case series
by: Stefania Nicola, et al.
Published: (2018-11-01)

Treatment with secukinumab in multi-comorbid patients with psoriatic arthritis
by: Ombretta Viapiana, et al.
Published: (2018-12-01)

Experience in using secukinumab in patients with axial psoriatic arthritis
by: E. E. Gubar, et al.
Published: (2020-11-01)

Evaluation of effectiveness and safety of Etanercept in children with Juvenile psoriatic arthritis
by: K. V. Aleksanyan, et al.
Published: (2020-09-01)

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
by: Coates, L, et al.
Published: (2020)

Ankylosing spondylitis and psoriatic arthritis: clinical and economic consequences of the use of etanercept
by: Viola Sacchi, et al.
Published: (2010-06-01)

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
by: Baraliakos, X, et al.
Published: (2022)

The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
by: Strand, V, et al.
Published: (2022)

Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis
by: Juan José Alegre-Sancho, et al.
Published: (2023-11-01)

Interleukin 17A inhibitor secukinumab in the treatment of patients with psoriatic arthritis
by: N. A. Shostak, et al.
Published: (2022-10-01)

LP-212 SLE overlap with psoriatic arthritis successfully treated with secukinumab
by: Athina Theodoridou
Published: (2023-07-01)

Cutaneous Vasculitis with Gut Involvement During Secukinumab Treatment for Psoriatic Arthritis
by: Clara Chelli, et al.
Published: (2020-03-01)

The effect of secukinumab treatment on hematological parameters in ankylosing spondylitis and psoriatic arthritis
by: Ahmet Karataş, et al.
Published: (2020-10-01)

Long term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease
by: Reich, K, et al.
Published: (2019)

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
by: Paolo Gisondi, et al.
Published: (2022-04-01)

Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement
by: G. Adami, et al.
Published: (2023-05-01)

Secukinumab in the therapy of psoriasis and psoriatic arthritis: a safe choice in clinical practice
by: Andrea Chiricozzi
Published: (2018-12-01)

Description of the Clinical Case of Adalimumab and Secukinumab Therapy of a Patient with Psoriatic Arthritis
by: V. V. Didenko, et al.
Published: (2021-05-01)

Effects of TNF-α inhibition secukinumab on active ultrasound-confirmed enthesitis in psoriatic arthritis
by: Ashley Elliott, et al.
Published: (2023-11-01)

Short-term Efficacy and Safety of Secukinumab in Pakistani Patients with Ankylosing Spondylitis and Psoriatic Arthritis
by: Sumera Ghani, et al.
Published: (2023-06-01)

A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab
by: M. Galluzzo, et al.
Published: (2018-11-01)

Etanercept
by: Sibel Alper
Published: (2022-04-01)

Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study
by: C. Bonifati, et al.
Published: (2020-10-01)

Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies
by: Renaud Felten, et al.
Published: (2023-10-01)

SUCCESSFUL USE OF AN INTERLEUKIN 17 INHIBITOR (SECUKINUMAB) IN THE TREATMENT OF ISOLATED DESTRUCTIVE ENTHESITIS IN PSORIATIC ARTHRITIS
by: E. E. Gubar, et al.
Published: (2018-11-01)

Efficacy and safety of secukinumab in patients with psoriatic arthritis: A meta-analysis of different dosing regimens
by: Kai-Lin Zhang, et al.
Published: (2021-10-01)

Secukinumab
by: Nilgün Atakan
Published: (2022-04-01)

Combining secukinumab and apremilast to successfully treat refractory psoriatic skin and joint disease: A novel approach
by: Muhammad K. Nisar
Published: (2019-01-01)